-
Jul 26, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel
Source/Disclosures
Source:
Slomovitz BM, et al. Abstract 427956. Presented at: ASCO Plenary Series: July 2023 Session; July 25, 2023.
Disclosures:
Karyopharm Therapeutics provided research funding for this study. Slomovitz reports consultant/advisory roles with Agenus, AstraZeneca, Eisai, Eli Lilly & Co., EQRx; Genentech, GOG Foundation, GSK, Incyte, Merck, Myriad Genetics, Nuvation Bio, Onconova Therapeutics and Regeneron.
-
Jul 25, 2023 | 
healio.com | Devin McLaughlin |Jashodeep Datta
Jashodeep Datta, MD
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy, owing in part to the fact that most patients present with advanced disease, with only 20% of patients eligible for surgical resection. The dismal oncologic outcomes with surgery alone, and the near universal distant failure, in patients with operable PDAC have mandated a multimodality approach for this disease.
-
Jul 25, 2023 | 
healio.com | Matthew Shinkle |Devin McLaughlin |Alex Herrera |Álex Herrera |Stephen Ansell
Source/Disclosures
Source:
Herrera AF, et al. Abstract LBA4. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023: Chicago.
Disclosures:
NCI and NIH funded this study.
-
Jul 24, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
A phase 3 trial of magrolimab plus azacitidine for higher-risk myelodysplastic syndrome has been terminated because of futility, according to a press release.
-
Jul 19, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
The addition of pembrolizumab to concurrent chemoradiotherapy conferred a statistically significant and clinically meaningful increase in PFS among women with newly diagnosed high-risk locally advanced cervical cancer, topline data showed.
-
Jun 15, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel
Source/Disclosures
Source:
ASCO in Action. ASCO chief medical officer testifies to Congress on mitigating and preventing cancer drug shortages. Available at: https://old-prod.asco.org/news-initiatives/policy-news-analysis/asco-chief-medical-officer-testifies-congress-mitigating-and. Published June 13, 2023. Accessed June 14, 2023.
We were unable to process your request. Please try again later.
-
Jun 8, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel |Jun Ma
Source/Disclosures Source: Ma J, et al. Abstract LBA6002. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Ma reports research funding from Bristol Myers Squibb and Varian Medical Systems. Please see the abstract for all other researchers’ relevant financial disclosures. We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
-
Jun 5, 2023 | 
healio.com | Devin McLaughlin |Mindy Valcarcel
Source/Disclosures
Source:
De Botton S, et al. Abstract 7012. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Disclosures:
De Botton reports relationships with AbbVie, Astellas Amgen BioPharama, Auron Therapeutics, Bristol Myers Squibb, Forma Therapeutics, GSK, Jazz Pharmaceuticals, Loxo Oncology, Remix Therapeutics, Servier and Syndax. Please see the abstract for all other researchers’ relevant financial disclosures.
-
Jun 5, 2023 | 
healio.com | Devin McLaughlin |Funda Meric-Bernstam |Bradley Alexander McGregor
Source/Disclosures
Source:
Meric-Bernstam F, et al. Abstract LBA3000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Disclosures:
AstraZeneca and Daiichi Sankyo supported this study.
-
Jun 5, 2023 | 
healio.com | Devin McLaughlin
Source/Disclosures Source: Cortés J, et al. Abstract LBA506. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Roche sponsored this research. Cortes reports stock ownership in Leuko, MedSIR and Nektar Therapeutics, as well as relationships with AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche and several other companies. Please see the abstract for all other researchers’ relevant financial disclosures.
